GlaxoSmithKline (CAI:BIOC) Other Stockholders Equity: E£82 Mil (As of Sep. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlaxoSmithKline Other Stockholders Equity?

GlaxoSmithKline CAI:BIOC +20.00% Other Stockholders Equity is E£82 Mil as of Sep. 2016.

GlaxoSmithKline's Other Stockholders Equity for the quarter that ended in Sep. 2016 was E£82 Mil.

GlaxoSmithKline's quarterly Other Stockholders Equity increased from Mar. 2016 (E£82 Mil) to Jun. 2016 (E£82 Mil) but then declined from Jun. 2016 (E£82 Mil) to Sep. 2016 (E£82 Mil).

GlaxoSmithKline's annual Other Stockholders Equity increased from Dec. 2013 (E£76 Mil) to Dec. 2014 (E£79 Mil) and increased from Dec. 2014 (E£79 Mil) to Dec. 2015 (E£82 Mil).

GlaxoSmithKline Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Other Stockholders Equity Chart

GlaxoSmithKline Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Other Stockholders Equity
72.12 75.83 79.11 82.36

GlaxoSmithKline Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.11 82.36 82.36 82.36 82.36

GlaxoSmithKline Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of E£82 Mil mean?
GlaxoSmithKline (CAI:BIOC) has a Other Stockholders Equity of E£82 Mil as of Sep. 2016. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Other Stockholders Equity too high?
GlaxoSmithKline's current Other Stockholders Equity is E£82 Mil.
How does GlaxoSmithKline's Other Stockholders Equity compare to PRPH?
GlaxoSmithKline's Other Stockholders Equity of E£82 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on GlaxoSmithKline and its competitors. GlaxoSmithKline's current Other Stockholders Equity is E£82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Other Stockholders Equity of E£82 Mil. The current Other Stockholders Equity is E£82 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Other Stockholders Equity is E£82 Mil as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.